Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Simcere Acquires Manufacturing Rights For Generic Crestor In China; Hopes Sales Force Will Provide Edge Over Competition

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Chinese firm Simcere signed an agreement with Tianjin Tianda Pharmaceutical to acquire the manufacturing license in China for Tianda's rosuvastatin, a generic version of AstraZeneca's cholesterol and atherosclerosis treatment Crestor (rosuvastatin), Simcere announced Nov. 9

You may also be interested in...



Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China

SHANGHAI - Merck & Co. affiliate MSD signed an agreement to form a joint venture July 21 with Simcere Pharmaceutical Group that will see both companies expand access to critical lifestyle drugs across China

Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China

SHANGHAI - Merck & Co. affiliate MSD signed an agreement to form a joint venture July 21 with Simcere Pharmaceutical Group that will see both companies expand access to critical lifestyle drugs across China

Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China

The deal also signals Merck's partnering strategy in emerging markets for its branded and innovative products, especially in Asia. The company expects EMs to contribute 25% of Merck's global sales by 2013.

Related Content

UsernamePublicRestriction

Register

SC070334

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel